Isomorphic Labs Raises $5B for AI Drug Discovery
Isomorphic Labs has closed a $5 billion Series C co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining as a new investor and Alphabet and existing backers also investing. The company plans to advance IsoDDE and move drug candidates toward clinical trials, though it has not disclosed its final valuation and no internally developed drug has entered human trials. Isomorphic Labs says IsoDDE improves predictions of drug binding and docking sites beyond AlphaFold 3, a claim not independently verified in the reports.
The financing is a major capital commitment to AI-driven drug discovery, but clinical validation remains the key unresolved milestone for Isomorphic Labs.
Isomorphic Labs raises $5 billion in its second mega-round within six months
Maximilian Schreiner View the LinkedIn Profile of Maximilian Schreiner
Nov 17, 2026
Alphabet's AI drug discovery company Isomorphic Labs has raised $5 billion, its second billion-dollar round in six months. Greenoaks and Sequoia Capital co-led the round, joined by new backer Andreessen Horowitz along with Alphabet and all existing investors.
The company had already raised $2.1 billion back in May 2026. The money will go toward advancing its in-house platform IsoDDE (Isomorphic Drug Design Engine) and pushing its drug pipeline toward clinical trials. IsoDDE goes beyond AlphaFold 3, according to the company founded in 2021, and aims to better predict drug binding and docking sites. Isomorphic Labs works with Novartis, Eli Lilly, and Johnson & Johnson but has no approved drug to show for it yet.
The company is led by Demis Hassabis, who stepped down from day-to-day leadership of Google Deepmind in August 2026 and now serves as Alphabet's Chief Scientist. Hassabis won the 2024 Nobel Prize in Chemistry alongside John Jumper for their work on AlphaFold.
#Isomorphic Labs#IsoDDE#Alphabet#Greenoaks#Sequoia Capital#Andreessen Horowitz#AlphaFold 3#Demis Hassabis